Details of the Drug

General Information of Drug (ID: DMFKXDY)

Drug Name

Fenofibrate

Synonyms

Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate

Indication

Disease Entry	ICD 11	Status	REF
High cholesterol level	5C80.0	Approved	[1], [2]

Therapeutic Class

Antilipemic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

360.8

Topological Polar Surface Area (xlogp)

5.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 6-9.5 mg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4-6 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The apparent oral clearance of drug is 1.1 L/h [5]
Elimination: 5-25% of a dose of fenofibrate is eliminated in the feces, while 60-88% is eliminated in the urine [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 23 hours [7]
Metabolism: The drug is metabolized via the liver carboxylesterase 1 to fenofibric acid [8]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.7406 micromolar/kg/day [9]
Vd: The volume of distribution (Vd) of drug is 60 L [3]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0008 mg/mL [4]

Chemical Identifiers

Formula: C20H21ClO4
IUPAC Name: propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
Canonical SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
InChI: InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
InChIKey: YMTINGFKWWXKFG-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3339
ChEBI ID: CHEBI:5001
CAS Number: 49562-28-9
DrugBank ID: DB01039
TTD ID: D07XGR
VARIDT ID: DR00415
INTEDE ID: DR0688
ACDINA ID: D00268

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor alpha (PPARA)	TTJ584C	PPARA_HUMAN	Agonist	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[12]
Carboxylesterase 1 (CES1)_{Main DME}	DEB30C5	EST1_HUMAN	Substrate	[]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

High cholesterol level

ICD Disease Classification

5C80.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Peroxisome proliferator-activated receptor alpha (PPARA)	DTT	PPARA	1.74E-01	-0.17	-0.3
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.76E-01	-4.64E-01	-9.16E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fenofibrate

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Fenofibrate and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[36]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Fenofibrate and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[37]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Fenofibrate and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[38]
-----------

Coadministration of a Drug Treating the Disease Different from Fenofibrate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Fenofibrate and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[39]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Fenofibrate and Insulin-glulisine.	Acute diabete complication [5A2Y]	[40]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Fenofibrate and Insulin-aspart.	Acute diabete complication [5A2Y]	[41]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Fenofibrate and Glipizide.	Acute diabete complication [5A2Y]	[40]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Fenofibrate and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[42]
Cilostazol	DMZMSCT	Moderate	Decreased metabolism of Fenofibrate caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[43]
Roflumilast	DMPGHY8	Moderate	Decreased metabolism of Fenofibrate caused by Roflumilast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[39]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Fenofibrate and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[44]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Fenofibrate caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[45]
Anisindione	DM2C48U	Major	Increased plasma concentration of Fenofibrate and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[46]
Mestranol	DMG3F94	Moderate	Decreased metabolism of Fenofibrate caused by Mestranol mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[39]
Escitalopram	DMFK9HG	Moderate	Decreased metabolism of Fenofibrate caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[39]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Fenofibrate caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Phenobarbital	DMXZOCG	Moderate	Decreased metabolism of Fenofibrate caused by Phenobarbital mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Fenofibrate and Cannabidiol.	Epileptic encephalopathy [8A62]	[47]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Fenofibrate and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[48]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Fenofibrate caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Fenofibrate caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[47]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Fenofibrate caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[50]
Quazepam	DMY4D87	Moderate	Decreased metabolism of Fenofibrate caused by Quazepam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Proguanil	DMBL79I	Moderate	Decreased metabolism of Fenofibrate caused by Proguanil mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[39]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Fenofibrate and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[51]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Fenofibrate and Idelalisib.	Mature B-cell leukaemia [2A82]	[52]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Fenofibrate caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[39]
Siponimod	DM2R86O	Major	Decreased metabolism of Fenofibrate caused by Siponimod mediated inhibition of CYP450 enzyme.	Multiple sclerosis [8A40]	[39]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Fenofibrate caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[47]
Ibuprofen	DM8VCBE	Moderate	Decreased metabolism of Fenofibrate caused by Ibuprofen mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[39]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Fenofibrate caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[53]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Fenofibrate and Leflunomide.	Rheumatoid arthritis [FA20]	[37]
As-1670542	DMV05SW	Moderate	Decreased metabolism of Fenofibrate caused by As-1670542 mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[39]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Fenofibrate and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[40]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Fenofibrate and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[40]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Fenofibrate and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[40]
-----------


⏷ Show the Full List of 33 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
Docusate sodium	E00563	23673837	Surfactant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hydrogenated polyoxyl 40 castor oil	E00662	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Poloxamer 407	E00646	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 20000	E00650	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium dihydrogenorthophosphate	E00559	23672064	Buffering agent; Complexing agent
Sodium laureth-3 sulfate	E00564	23674622	Surfactant
Soybean lecithin	E00637	Not Available	Other agent
Sulfur dioxide	E00046	1119	Antioxidant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Tocophersolan	E00679	Not Available	Antioxidant; Binding agent; Emulsifying agent; Ointment base; Solubilizing agent; Surfactant; Suspending agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 53 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fenofibrate 134 mg capsule	134 mg	Oral Capsule	Oral
Fenofibrate 200 mg capsule	200 mg	Oral Capsule	Oral
Fenofibrate 67 mg capsule	67 mg	Oral Capsule	Oral
Fenofibrate 130 mg capsule	130 mg	Oral Capsule	Oral
Fenofibrate 43 mg capsule	43 mg	Oral Capsule	Oral
Fenofibrate 50 mg tablet	50 mg	Oral Tablet	Oral
Fenofibrate 90 mg capsule	90 mg	Oral Capsule	Oral
Fenofibrate 50 mg capsule	50 mg	Oral Capsule	Oral
Fenofibrate 30 mg capsule	30 mg	Oral Capsule	Oral
Fenofibrate 150 mg capsule	150 mg	Oral Capsule	Oral
Fenofibrate 54 mg tablet	54 mg	Oral Tablet	Oral
Fenofibrate 145 mg tablet	145 mg	Oral Tablet	Oral
Fenofibrate 48 mg tablet	48 mg	Oral Tablet	Oral
Fenofibrate 120 mg tablet	120 mg	Oral Tablet	Oral
Fenofibrate 40 mg tablet	40 mg	Oral Tablet	Oral
Fenofibrate 160 mg tablet	160 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7186).
2	Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81.
3	Balfour JA, McTavish D, Heel RC: Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990 Aug;40(2):260-90. doi: 10.2165/00003495-199040020-00007.
4	BDDCS applied to over 900 drugs
5	FDA Approved Drug Products: Fenofibrate Oral Tablets
6	Chapman MJ: Pharmacology of fenofibrate. Am J Med. 1987 Nov 27;83(5B):21-5. doi: 10.1016/0002-9343(87)90867-9.
7	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62. doi: 10.2165/00003088-199834020-00003.
8	Simmons RE, Hjelle JT, Mahoney C, Deftos LJ, Lisker W, Kato P, Rabkin R: Renal metabolism of calcitonin. Am J Physiol. 1988 Apr;254(4 Pt 2):F593-600. doi: 10.1152/ajprenal.1988.254.4.F593.
9	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
11	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
12	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
13	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
23	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
24	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
25	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
26	The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
27	Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
28	Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
29	Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
30	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
31	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
32	Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
33	Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
34	Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
35	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
36	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
37	Canadian Pharmacists Association.
38	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
39	Cerner Multum, Inc. "Australian Product Information.".
40	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
41	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
42	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
43	Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
44	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
45	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
46	Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997): 615-33. [PMID: 9339964]
47	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
48	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
49	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
50	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
51	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
52	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
53	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.